Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Italy: NHS facts and figures:

This article was originally published in Clinica

Executive Summary

There are 1,117 public hospitals in Italy with some 301,668 beds, according to a recent healthcare feature in Il Sole-24 Ore. Just over 600 private and non-profit hospitals are also contracted to carry out services on behalf of the national health service. Some 8.2 million patients are treated annually in hospital at an average cost of Lit 5.8 million ($3,500) each, accounting for a total of nearly 80 million patient days. The ratio of practising doctors to inhabitants is 1:187. A total of 73,601 doctors work in the hospital sector, although there is still a surplus of qualified doctors in the country. National healthcare service spending totalled Lit 91,619,000 million in 1994, Lit 19,218,000 of which was spent on goods and services. Private healthcare spending amounted to Lit 33,476,000 million.

You may also be interested in...



US FDA Still Seeking Sponsor Cooperation For Oncology Label Updates

Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.

Oncology Drug Safety Is Key Focus In US FDA’s Generic Label Updates

US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.

EU GMP Annex I Proposal Would Maintain PUPSIT, Relax WFI Restrictions

The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.

Topics

UsernamePublicRestriction

Register

MT091683

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel